Ketchum, Steven B.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 3,317

Effects of Icosapent Ethyl on Total Ischemic Events

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 259

Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 183

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States

Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 136

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 61

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 29

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 9

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 0